Renata R Urban1, Hao He2, Raphael Alfonso2, Melissa M Hardesty3, Heidi J Gray4, Barbara A Goff4. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, United States. Electronic address: urbanr@u.washington.edu. 2. Surgical Outcomes Research Center, University of Washington, Seattle, WA, United States. 3. Alaska Women's Cancer Care, Anchorage, AK, United States. 4. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, United States.
Abstract
OBJECTIVE: To describe the outcomes and mortality in advanced ovarian cancer patients in a population-based cohort in the 90 days after diagnosis. METHODS: Using the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database, we identified a cohort of women with stage III/IV epithelial ovarian cancer diagnosed between 1995 and 2007. A χ(2) test was used to assess demographic and clinical factors. Kaplan-Meier curves and Cox proportional hazards models were used to assess factors associated with variation in survival. RESULTS: Of the 9491 patients with stage III/IV ovarian cancer identified from the SEER/Medicare system, 4131 (43.6%) patients died in the first year after diagnosis. Of these, 2472 (26.0%) patients died in the first 90 days after diagnosis. Over the study period, the number of patients who died in the first 90 days after diagnosis slightly increased (p=0.053). Older age (>75 years of age), increased comorbidity, stage IV disease, lack of a visit with a gynecologic oncologist, and surgery were associated with an increase in 90-day mortality. Chemotherapy was associated with a reduction in 90-day mortality. CONCLUSIONS: Approximately 25% of patients with advanced ovarian cancer in our study period died within 90 days of diagnosis, and more than 40% died within the first year of diagnosis. In addition, a substantial proportion of patients did not receive any treatment. Further research into the characteristics of these patients should be performed to elucidate clinical areas for intervention to either prevent these poor outcomes or allocate appropriate resources to patients with extremely poor prognoses.
OBJECTIVE: To describe the outcomes and mortality in advanced ovarian cancerpatients in a population-based cohort in the 90 days after diagnosis. METHODS: Using the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database, we identified a cohort of women with stage III/IV epithelial ovarian cancer diagnosed between 1995 and 2007. A χ(2) test was used to assess demographic and clinical factors. Kaplan-Meier curves and Cox proportional hazards models were used to assess factors associated with variation in survival. RESULTS: Of the 9491 patients with stage III/IV ovarian cancer identified from the SEER/Medicare system, 4131 (43.6%) patients died in the first year after diagnosis. Of these, 2472 (26.0%) patients died in the first 90 days after diagnosis. Over the study period, the number of patients who died in the first 90 days after diagnosis slightly increased (p=0.053). Older age (>75 years of age), increased comorbidity, stage IV disease, lack of a visit with a gynecologic oncologist, and surgery were associated with an increase in 90-day mortality. Chemotherapy was associated with a reduction in 90-day mortality. CONCLUSIONS: Approximately 25% of patients with advanced ovarian cancer in our study period died within 90 days of diagnosis, and more than 40% died within the first year of diagnosis. In addition, a substantial proportion of patients did not receive any treatment. Further research into the characteristics of these patients should be performed to elucidate clinical areas for intervention to either prevent these poor outcomes or allocate appropriate resources to patients with extremely poor prognoses.
Authors: Tomi F Akinyemiju; Gurudatta Naik; Kemi Ogunsina; Daniel T Dibaba; Neomi Vin-Raviv Journal: Cancer Causes Control Date: 2018-02-10 Impact factor: 2.506
Authors: Julia L Boland; Qin Zhou; Alexia E Iasonos; Roisin E O'Cearbhaill; Jason Konner; Margaret Callahan; Claire Friedman; Carol Aghajanian; Paul Sabbatini; Dmitriy Zamarin; Karen A Cadoo Journal: Gynecol Oncol Date: 2020-06-02 Impact factor: 5.482
Authors: Xiaoman Hou; Yali Zhai; Kevin Hu; Chia-Jen Liu; Aaron Udager; Celeste L Pearce; Eric R Fearon; Kathleen R Cho Journal: Gynecol Oncol Date: 2022-04-09 Impact factor: 5.304
Authors: Yueying Liu; Jing Yang; Zonggao Shi; Xuejuan Tan; Norman Jin; Catlin O'Brien; Connor Ott; Anna Grisoli; Eric Lee; Kelly Volk; Meghan Conroy; Emily Franz; Annamarie Bryant; Leigh Campbell; Brian Crowley; Stephen Grisoli; Aris T Alexandrou; Chunyan Li; Elizabeth I Harper; Marwa Asem; Jeff Johnson; Annemarie Leonard; Katie Santanello; Ashley Klein; Qingfei Wang; Siyuan Zhang; Tyvette S Hilliard; M Sharon Stack Journal: Cancer Lett Date: 2021-01-30 Impact factor: 8.679
Authors: Amy L Shafrir; Ana Babic; Rulla M Tamimi; Bernard A Rosner; Shelley S Tworoger; Kathryn L Terry Journal: Br J Cancer Date: 2016-10-04 Impact factor: 7.640